Kazuo Fujihara

Hot topics in NMOSD: immunological & clinical considerations 2:22
Hot topics in NMOSD: immunological & clinical considerations
Kazuo Fujihara • 28 Oct 2022
METEOROID: Phase III trial of satralizumab in patients with MOGAD 2:21
METEOROID: Phase III trial of satralizumab in patients with MOGAD
Kazuo Fujihara • 28 Oct 2022
Current diagnostic and treatment measures for AQP4-IgG-positive NMOSD 5:25
Current diagnostic and treatment measures for AQP4-IgG-positive NMOSD
Kazuo Fujihara • 28 Oct 2022
Unmet needs in the diagnostics and treatment of NMOSD 3:00
Unmet needs in the diagnostics and treatment of NMOSD
Kazuo Fujihara • 28 Oct 2022
New agents under investigation to treat AQP4-positive NMOSD 1:32
New agents under investigation to treat AQP4-positive NMOSD
Kazuo Fujihara • 28 Oct 2022
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD 5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara • 4 Oct 2021
Novel treatment strategies for NMOSD 1:21
Novel treatment strategies for NMOSD
Kazuo Fujihara • 4 Oct 2021
Symptomatic treatment of NMOSD 2:24
Symptomatic treatment of NMOSD
Kazuo Fujihara • 4 Oct 2021
Diagnostic criteria and treatment updates for NMOSD 5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara • 4 Oct 2021
The content of VJNeurology is intended for healthcare professionals